Abstract
Blood platelets play a key role in normal hemostasis but also in atherothrombosis due to their ability of thrombus formation at site of a ruptured atherosclerotic plaque. Platelets are also involved in vascular inflammation due to interactions with endothelial cells, leukocytes, and smooth muscle cells that may result in an excessive fibroproliferative response after vessel dilatation. This review article describes both, the current status of standard anti-platelet drug therapy using acetylsalicylic acid, adenosine diphosphate or glycoprotein IIb-IIIa receptor antagonists in the prevention of cardiovascular events as well as drawbacks like non-responsiveness or increased bleeding rates leading to enhanced reintervention and transfusion rates, both responsible for adverse clinical outcomes after coronary interventions.
Keywords: Abciximab, acetylsalicylic acid, acute coronary syndromes, clopidogrel, fibrinogen receptor antagonists, platelet function, platelet receptor blockade, prasugrel, thienopyridines, thromboxane A2 receptor antagonists, thrombin receptor antagonists, vorapaxar
Cardiovascular & Hematological Agents in Medicinal Chemistry
Title:Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks
Volume: 11 Issue: 1
Author(s): Susanne M. Picker
Affiliation:
Keywords: Abciximab, acetylsalicylic acid, acute coronary syndromes, clopidogrel, fibrinogen receptor antagonists, platelet function, platelet receptor blockade, prasugrel, thienopyridines, thromboxane A2 receptor antagonists, thrombin receptor antagonists, vorapaxar
Abstract: Blood platelets play a key role in normal hemostasis but also in atherothrombosis due to their ability of thrombus formation at site of a ruptured atherosclerotic plaque. Platelets are also involved in vascular inflammation due to interactions with endothelial cells, leukocytes, and smooth muscle cells that may result in an excessive fibroproliferative response after vessel dilatation. This review article describes both, the current status of standard anti-platelet drug therapy using acetylsalicylic acid, adenosine diphosphate or glycoprotein IIb-IIIa receptor antagonists in the prevention of cardiovascular events as well as drawbacks like non-responsiveness or increased bleeding rates leading to enhanced reintervention and transfusion rates, both responsible for adverse clinical outcomes after coronary interventions.
Export Options
About this article
Cite this article as:
M. Picker Susanne, Antiplatelet Therapy in the Prevention of Coronary Syndromes: Mode of Action, Benefits, Drawbacks, Cardiovascular & Hematological Agents in Medicinal Chemistry 2013; 11 (1) . https://dx.doi.org/10.2174/1871525711311010009
DOI https://dx.doi.org/10.2174/1871525711311010009 |
Print ISSN 1871-5257 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6182 |
Call for Papers in Thematic Issues
Medicinal Plants with Beneficial Properties on Diabetes and Hypertension
Diabetes and hypertension are real scourges of the 21st century. It is imperative to act in order to find innovative solutions to this problem. Taking medications such as hypoglycemic and antihypertensive drugs may aggravate certain underlying comorbidities, such as chronic kidney disease and cardiovascular disease. This significant drawback therefore requires ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Synthesis and Evaluation of Indole Based Molecules for Treatment of Oxidative Stress Related Diseases
Current Topics in Medicinal Chemistry The Impact of Phytosterols on the Healthy and Diseased Brain
Current Medicinal Chemistry Proteomics and Mass Spectrometry: What Have We Learned About The Heart?
Current Cardiology Reviews Strategies to Tackle Early Low Flow States in the Extremely Preterm Infant
Current Pediatric Reviews Ezetimibe and Vascular Endothelial Function
Current Vascular Pharmacology The Role of Size in Development of Mucosal Liposome-Lipopeptide Vaccine Candidates Against Group A Streptococcus
Medicinal Chemistry Pediatric CKD and Cardivascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism The Fibroblast Growth Factor 23: A New Player in the Field of Cardiovascular, Bone and Renal Disease
Current Vascular Pharmacology Expression and Role of the Calcium-Sensing Receptor in the Blood Vessel Wall
Current Pharmaceutical Biotechnology Metabolic Syndrome Components in Murine Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Mediterranean Diet and Risk of Dementia
Current Alzheimer Research Phosphodiesterase 10 Inhibitors: New Disease Modifying Drugs for Parkinson’s Disease?
Current Medicinal Chemistry Alzheimer’s Disease is Associated with Increased Risk of Osteoporosis: The Chongqing Aging Study
Current Alzheimer Research Can microRNAs be Biomarkers or Targets for Therapy of Ischemic Coronary Artery Disease in Metabolic Syndrome?
Current Drug Targets Statins in the Treatment of Acute Ischemic Stroke
Current Pharmaceutical Biotechnology Biologic Therapies in Primary Sjögren's Syndrome
Current Pharmaceutical Biotechnology Effect of Non-Statin Lipid Lowering and Anti-Obesity Drugs on LDL Subfractions in Patients with Mixed Dyslipidaemia
Current Vascular Pharmacology Vascular Dysfunction and Insulin Resistance in Aging
Current Vascular Pharmacology Therapy Against Ischemic Injury
Current Pharmaceutical Design